Novartis gets speedy review for CAR-T cell therapy

30th March 2017 Uncategorised 0

Novartis has stepped ahead in the race to get the first cancer-killing CAR-T cell therapy on the market having successfully filed a biologics license application with US regulators.

More: Novartis gets speedy review for CAR-T cell therapy
Source: News